Carlton Yuen, MD
Ophthalmology · Honolulu, HINPI 1104991611
Payments from drug & device makers
Across 523 payments — averaging $841.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$385K
- Alcon$32K
- Dompe US, Inc.$15K
- Sight Sciences, Inc.$1K
- Bausch & Lomb Americas Inc.$808
- Sun Pharmaceutical Industries Inc.$786
- plus $5K from 19 others
What the payments were for
- Consulting fees$116,67567%
- Speaking & faculty fees$21,72512%
- Travel & lodging$17,22210%
- Food & beverage$18,06010%
- Gifts$190%
- Other$8380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 177 | $385,224 |
| Alcon | 53 | $31,615 |
| Dompe US, Inc. | 44 | $15,056 |
| Sight Sciences, Inc. | 15 | $1,253 |
| Bausch & Lomb Americas Inc. | 24 | $808 |
| Sun Pharmaceutical Industries Inc. | 20 | $786 |
| NEW World Medical,inc. | 3 | $780 |
| Amgen(2 entities) | 39 | $717 |
| AbbVie(2 entities) | 35 | $622 |
| Oyster Point Pharma, Inc. | 8 | $513 |
| Aerie Pharmaceuticals, Inc. | 5 | $423 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 31 | $348 |
| Merz Pharmaceuticals, LLC | 11 | $309 |
| Glaukos Corporation | 4 | $269 |
| Novartis | 12 | $244 |
| Johnson & Johnson Vision Care, Inc. | 4 | $236 |
| Tarsus Pharmaceuticals, Inc. | 15 | $231 |
| Kala Pharmaceuticals, Inc. | 8 | $170 |
| Genentech USA, Inc. | 6 | $108 |
| Rxsight Inc | 2 | $92 |
| Shire North American Group Inc | 3 | $59 |
| Beaver-visitec International, Inc. | 1 | $48 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Merz North America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$187,841
- TRYPTYR$24,024
- Oxervate$14,199
- Tecnis Symfony IOL$13,627
- Tecnis Multifocal Family of 1-piece IOLS$12,183
- LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE)$10,284
- Catalys Laser System$4,724
- ARGOS$4,598
- Clareon$4,498
- Centurion$4,387
- Tecnis Simplicity$4,126
- VERITAS Vision System$4,111
- CATALYS SYSTEM$3,197
- Tecnis Symphony IOL$2,750
- Tecnis Symphony Toric IOL$2,750
- ELITA$2,568
- Tecnis 1-piece IOL$1,476
- OMNI(R) SURGICAL SYSTEM (US)$1,020
- Tecnis Symfony Toric IOL$1,019
- Unity$838
How this compares
$439,959 in reported general payments places this provider in the 95th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 20 | $638,402 |
| RestasisCyclosporine | 33 | $46,787 |
| RocklatanNetarsudil Mesylat/Latanoprost | 25 | $22,261 |
| XdemvyLotilaner | 12 | $21,719 |
| LumiganBimatoprost | 28 | $21,089 |
| Loteprednol Etabonate | 88 | $17,142 |
| Prednisolone Acetate | 312 | $15,771 |
| EysuvisLoteprednol Etabonate | 28 | $13,870 |
| VyzultaLatanoprostene Bunod | 22 | $12,978 |
| Latanoprost | 479 | $9,765 |
| Alphagan PBrimonidine Tartrate | 15 | $9,193 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $9,142 |
| MieboPerfluorohexyloctane/Pf | 11 | $8,317 |
| Brimonidine Tartrate | 71 | $6,626 |
| RhopressaNetarsudil Mesylate | 13 | $6,189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $15,056 | $638,40220 claims |
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $622 | $86,21193 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $423 | $28,45038 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $231 | $21,71912 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Miebo | $808 | $21,29533 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $348 | $17,14288 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $170 | $13,87028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Honolulu
- Neda NikpoorHonolulu$322K
- Alan FaulknerHonolulu$207K
- Michael BennettHonolulu$190K
- Jeffrey PetersonHonolulu$85K
- Rupa WongHonolulu$72K
- Worldster LeeHonolulu$30K
- Elysse TomHonolulu$20K
- Jon PortisHonolulu$20K
- Tyrie JenkinsHonolulu$19K
- John OlkowskiHonolulu$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.